STAT August 19, 2024
Allison DeAngelis

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked.

The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.

The founders were a medical school dropout, an entrepreneur whose most recent success was with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article